Adhera Therapeutics, Inc. (ATRX)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jan 21, 2025, 4:00 PM EST
Adhera Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
1.16K
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| Veradigm | 1.53B |
| SS Innovations International | 16.04M |
| Elite Pharmaceuticals | 71.17M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| Silence Therapeutics | 21.77M |
Adhera Therapeutics News
- 2 years ago - Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes - GlobeNewsWire
- 2 years ago - Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist - GlobeNewsWire
- 2 years ago - Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin - GlobeNewsWire
- 2 years ago - Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ - GlobeNewsWire
- 3 years ago - Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board - GlobeNewsWire
- 3 years ago - Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace - GlobeNewsWire
- 3 years ago - Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders - GlobeNewsWire
- 3 years ago - Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors - GlobeNewsWire